Economic Outcomes of Inflammatory Bowel Disease Patients Switching to a Second Anti-Tumor Necrosis Factor or Vedolizumab

BACKGROUND: Anti-tumor necrosis factor (TNF) therapies have been the mainstay of inflammatory bowel disease (IBD) treatment for nearly 2 decades. Therapies with novel mechanisms of action have been recently developed. This study compared healthcare resource utilization (HRU) and costs incurred while...

Descripción completa

Detalles Bibliográficos
Autores principales: Chiorean, Michael, Afzali, Anita, Cross, Raymond K, Macaulay, Dendy, Griffith, Jenny, Wang, Anthony, Garcia-Horton, Viviana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Observations and Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802429/
https://www.ncbi.nlm.nih.gov/pubmed/36777306
http://dx.doi.org/10.1093/crocol/otaa031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802429/
https://www.ncbi.nlm.nih.gov/pubmed/36777306
http://dx.doi.org/10.1093/crocol/otaa031

Ejemplares similares